Suppression of metastatic potential of high-metastatic Lewis lung carcinoma cells by vanadate, an inhibitor of tyrosine phosphatase, through inhibiting cell-substrate adhesion

Invasion and Metastasis

Volumn 16, Issue 2, 1996, Pages 97-106

  Takenaga, Keizo ^a  

^a CHIBA CANCER CENTER   (Japan)

Author keywords

Cell substrate adhesion; Lewis lung carcinoma; Metastasis; Tyrosine phosphorylation; Vanadate

Indexed keywords

ALPHA CYANO 3 ETHOXY 4 HYDROXY 5 (PHENYLTHIOMETHYL)CINNAMAMIDE; COLLAGEN TYPE 4; FIBRONECTIN; LAMININ; MATRIGEL; ORTHOVANADIC ACID; PROTEIN TYROSINE PHOSPHATASE; VANADIC ACID;

ANIMAL CELL; ARTICLE; BASEMENT MEMBRANE; CANCER INHIBITION; CELL ADHESION; CELL SPREADING; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME INHIBITION; ENZYME SUBSTRATE; LEWIS CARCINOMA; LUNG CARCINOMA; METASTASIS POTENTIAL; NONHUMAN; PROTEIN PHOSPHORYLATION;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, LEWIS LUNG; CELL ADHESION; CELL SIZE; CINNAMATES; COLLAGEN; DRUG COMBINATIONS; ENZYME INHIBITORS; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; LAMININ; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-TYROSINE-PHOSPHATASE; PROTEOGLYCANS; SULFIDES; TUMOR CELLS, CULTURED; VANADATES;

EID: 0030470250     PISSN: 02511789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Humphries MJ, Olden K, Yamada KM: A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 1986;233:467-470.
2. Humphries MJ, Yamada KM, Olden K: Investigation of the biological effects of anti-adhesive synthetic peptides which inhibit experimental metastasis. J Clin Invest 1988;81:782-790.
3. Saiki I, Ida J, Murata J, Ogawa R, Nishi N, Sugimura K, Tokura S, Azuma I: Inhibition of the metastasis of murine malignant melanoma by synthetic polymeric peptides containing core sequences of cell-adhesive molecules. Cancer Res 1989;49:3815-3822.
4. Iwamoto Y, Robey FA, Graf J, Sasaki M, Kleinman HK, Yamada Y, Martin GR: YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 1987;238:1132-1134.
5. Yamada KM, Kennedy DW, Yamada SS, Gralnick H, Chen WT, Akiyama SK: Monoclonal antibody and synthetic peptide inhibitors of human tumor cell migration. Cancer Res 1990;50:4485-4496.
6. Burridge K, Turner CE, Romer LH: Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: A role in cytoskeletal assembly. J Cell Biol 1992;119:893-903.
7. Guan JL, Shalloway D: Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature 1992;358:690-692.
8. Hanks SK, Calallb MB, Harper MC, Patel SK: Focal adhesion proteintyrosine kinase phosphorylated in response to cell attachment to fibronectin. Proc Natl Acad Sci USA 1992;89:8487-8491.
9. Kornberg L, Earp HS, Parsons JT, Schaller M, Juliano RL: Cell adhesion or integrin clustering increases phosphorylation of a focal adhesion-associated tyrosine kinase. J Biol Chem 1992;267:23439-23442.
10. Turner CE: Paxillin is a major phosphotyrosine-containing protein during embryonic development. J Cell Biol 1991;115:201-207.
11. Davis S, Lu ML, Lo SH, Lin S, Butler JA, Druker BJ, Roberts TM, An Q, Chen LB: Presence of an SH2 domain in the actin-binding protein tensin. Science 1991;252:712-715.
12. Sankar S, Mahooti-Brooks N, Hu G, Madri JA: Modulation of cell spreading and migration by pp125FAK phosphorylation. Am J Pathol 1995;147:601-608.
13. Matsumoto K, Matsumoto K, Nakamura T, Kramer KH: Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J Biol Chem 1994;269:31807-31813.
14. Kellie S, Horvath AR, Elmore MA: Cytoskeletal targets for oncogenic tyrosine kinases. J Cell Sci 1991;99:207-211.
15. Maher PA: Activation of phosphotyrosine phosphatase activity by reduction of cell-substrate adhesion. Proc Natl Acad Sci USA 1993;90:11177-11181.
16. Gaudry M, Caon AC, Gilbert C, Lille S, Naccache PH: Evidence for the involvement of tyrosine kinases in the locomotory responses of human neutrophils. J Leukoc Biol 1992;51:103-108.
17. 3 integrin in human fibroblasts. Cell Struct Funct 1995;20:403-413.
18. Bourgoin S, Grinstein S: Peroxides of vanadate induce activation of phospholipase D in HL-60 cells. Role of tyrosine phosphorylation. J Biol Chem 1992;267:11908-11916.
19. Volberg T, Zick Y, Dror R, Sabanay I, Gilon C, Levitzki A, Geiger B: The effect of tyrosine-specific protein phosphorylation on the assembly of adherens-type junctions. EMBO J 1992;11:1733-1742.
20. Rijksen G, Völler MCW, Van Zoelen EJJ: Orthovanadate both mimics and antagonizes the transforming growth factor β action on normal rat kidney cells. J Cell Physiol 1993;154:393-401.
21. Shiraishi T, Domoto T, Imai N, Shimada Y, Watanabe K: Specific inhibitors of tyrosine-specific protein kinase, synthetic 4-hydroxycinnamamide derivatives. Biochem Biophys Res Commun 1987;147:322-328.
22. Takenaga K, Nakamura Y, Endo H, Sakiyama S: Involvement of S100-related calcium binding protein pEL98 (or mts1) in cell motility and tumor cell invasion. Jpn J Cancer Res 1994;85:831-839.
23. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
24. Towbin H, Staehelin T, Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4354.
25. Fuortes M, Jin WW, Nathan C: Adhesion-dependent protein tyrosine phosphorylation in neutrophils treated with tumor necrosis factor. J Cell Biol 1993;120:777-784.
26. Nomura S, Fujimoto J, Okada M, Yamamoto T, Aizawa S: Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 1995;377:539-544.
27. 1 integrins in a weakly metastatic glycosylation mutant. Int J Cancer 1989;44:343-347.